

United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/046,289	01/16/2002	Henriette Gourdeau	PHARMA 100 D1	1982
24999	7590 03/26/2003			
MILLEN, WHITE, ZELANO & BRANIGAN, PC 2200 CLARENDON BLVD SUITE 1400			EXAMINER	
			GOLDBERG, JEROME D	
ARLINGTO	ARLINGTON, VA 22201		ART UNIT	PAPER NUMBER
			1614	A
			DATE MAILED: 03/26/2003	\mathcal{I}

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)			
		10/046,289	GOURDEAU ET AL.			
	Office Action Summary	Examiner	Art Unit			
		Jerome D Goldberg	1614			
	The MAILING DATE of this communication app	ears on the c ver sheet with the c	rrespondence address			
Period for Reply A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE <u>1</u> MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.						
 Extens after S If the p If NO p Failure Any rej 	ions of time may be available under the provisions of 37 CFR 1.13 X (6) MONTHS from the mailing date of this communication. eriod for reply specified above is less than thirty (30) days, a reply eriod for reply is specified above, the maximum statutory period w to reply within the set or extended period for reply will, by statute, bly received by the Office later than three months after the mailing patent term adjustment. See 37 CFR 1.704(b).	within the statutory minimum of thirty (30) days ill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONED	s will be considered timely. the mailing date of this communication. O (35 U.S.C. § 133).			
Status						
1)🖂	Responsive to communication(s) filed on 27 h	<u>1arch 2002</u> .				
2a) <u></u> □	This action is FINAL . 2b) ☐ Thi	s action is non-final.				
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213. Disposition of Claims						
·		n				
 4) ☐ Claim(s) 11-59 is/are pending in the application. 4a) Of the above claim(s) is/are withdrawn from consideration. 						
	Claim(s) is/are allowed.	m nom consideration.				
	6) Claim(s) is/are rejected.					
•	Claim(s) is/are objected to.					
	Claim(s) <u>11-59</u> are subject to restriction and/or	election requirement.				
Application Papers						
9) <u></u> ⊤	he specification is objected to by the Examiner	·.				
10)∐ T	10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.					
	Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).					
11)[] T	11)☐ The proposed drawing correction filed on is: a)☐ approved b)☐ disapproved by the Examiner.					
If approved, corrected drawings are required in reply to this Office action.						
12) The oath or declaration is objected to by the Examiner.						
Priority under 35 U.S.C. §§ 119 and 120						
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
a) All b) Some * c) None of:						
1. Certified copies of the priority documents have been received.						
2	2. Certified copies of the priority documents have been received in Application No					
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 						
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).						
a) ☐ The translation of the foreign language provisional application has been received. 15)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.						
Attachment(s)						
1) Notice	of References Cited (PTO-892) of Draftsperson's Patent Drawing Review (PTO-948)	· —	(PTO-413) Paper No(s) Patent Application (PTO-152)			
	ation Disclosure Statement(s) (PTO-1449) Paper No(s) 3		attent, upproduct (1.10-102)			



Art Unit: 1614

Claim 11-59 are drawn to compositions and method for treating leukemia employing an enhanced combination of a compound of formula I and a chemotherapeutic agent such as doxorubicin. Applicants state on page 22, lines 9-11 that this "combination extends the survival time of the mice substantially compound to either single agents B-L-oddC and Doxorubicin." Applicants are, therefore required to elect a single enhanced combination of one compound of formula I with one chemotherapeutic agent.

The several inventions above are independent and distinct, each from the other, as they have acquired a separate status in the art of treating leukemia as a separate subject matter for inventive effect and require independent searches. It is noted that a reference to one enhanced combination of drugs would not be a reference to another enhanced combination of drugs under 35 U.S.C. 103. Further, the claims read on a multitude of enhanced combinations of drugs which would require many field of searches that would be an undue burden on the Examiner. Therefore, restriction for examination purposes is proper.

Applicants are required to make a provisional election even though this requirement is traversed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jerome Goldberg whose telephone number is (703) 308-4606. The examiner can normally be reached on Monday-Thursday 9:00 A.M - 3:00 P.M.

Application/Control Number: 10/046,289

Art Unit: 1614

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Marianne Seidel can be reached on (703) 308-4725. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 305-4556 for regular communications and (703) 305-3592 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-1235.

Goldberg/tgd March 19, 2003 JEROME D. GOLDBERG PRIMARY EXAMINER